nach oben

HNO

Erschienen in:

01.07.2013 | Leitthema

Immuntherapie von Kopf-Hals-Karzinomen

Aktuelle Entwicklungen

verfasst von: Dr. P.J. Schuler, T.K. Hoffmann, T.C. Gauler, C. Bergmann, S. Brandau, S. Lang

Erschienen in: HNO | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Um die Prognose von Patienten mit Plattenepithelkarzinomen des Kopf-Hals-Bereichs (PKH) zu verbessern, ist die Weiterentwicklung der Immuntherapie notwendig, bei der tumorspezifische Antigene eine zielgerichtete onkologische Therapie ermöglichen. Gerade Patienten mit PKH verfügen aber über ausgeprägte immunsuppressive Mechanismen und Funktionseinschränkungen wichtiger Effektorzellen. Eine erfolgreiche Immuntherapie könnte durch die Restitution dieser Zellpopulationen eine effektive antitumorale Immunantwort induzieren. Gegenwärtige antitumorale immuntherapeutische Strategien umfassen u. a. die unspezifische Immunstimulation, genetische Modifikationen von Tumor- oder Immunzellen, die Verwendung monoklonaler Antikörper, wie z. B. Cetuximab, die adoptive Immuntherapie wie auch die Impfung. Diese biologischen Therapien könnten in Zukunft entweder allein oder in Kombination mit konventionellen Behandlungskonzepten eine wertvolle Therapieergänzung für Patienten mit PKH darstellen.

Albers AE, Ferris RL, Kim GG et al (2005) Immune responses to p53 in patients with cancer: enrichment in tetramer +p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 54:1072–1081PubMedCrossRef

Andrade Filho PA, Ito D, Deleo AB et al (2010) CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 59:1561–1568CrossRef

Badoual C, Hans S, Rodriguez J et al (2006) Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12:465–472PubMedCrossRef

Badoual C, Sandoval F, Pere H et al (2010) Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck 32:946–958PubMed

Balz V, Scheckenbach K, Gotte K et al (2003) Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 63:1188–1191PubMed

Barnea I, Haif S, Keshet R et al (2012) Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: Results of in vitro and in vivo studies. Head Neck [ePub]

Bazarbashi S, Rahal M, Raja MA et al (2002) A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma. Chemotherapy 48:211–216PubMedCrossRef

Bekeredjian-Ding I, Schafer M, Hartmann E et al (2009) Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha. Immunology 128:439–450PubMedCrossRef

Bergmann C, Strauss L, Wieckowski E et al (2009) Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck 31:371–380PubMedCrossRef

10.

Bergmann C, Strauss L, Zeidler R et al (2007) Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 67:8865–8873PubMedCrossRef

11.

Bianchini C, Ciorba A, Pelucchi S et al (2011) Targeted therapy in head and neck cancer. Tumori 97:137–141PubMed

12.

Bier H, Hoffmann T, Haas I et al (1998) Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 46:167–173PubMedCrossRef

13.

Bier H, Hoffmann T, Hauser U et al (2001) Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol 47:519–524PubMedCrossRef

14.

Bier J, Kleinschuster S, Bier H et al (1982) Intratumor immunotherapy with BCG cell wall preparations: development of a new therapy approach for head-neck tumors. Arch Otorhinolaryngol 236:245–255PubMedCrossRef

15.

Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578PubMedCrossRef

16.

Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28PubMedCrossRef

17.

Brandau S, Trellakis S, Bruderek K et al (2011) Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol 89:311–317PubMedCrossRef

18.

Bugis SP, Lotzova E, Savage HE et al (1990) Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancer. Cancer Immunol Immunother 31:176–181PubMedCrossRef

19.

Burtness B, Goldwasser MA, Flood W et al (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646–8654PubMedCrossRef

20.

Chikamatsu K, Albers A, Stanson J et al (2003) P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res 63:3675–3681PubMed

21.

Chikamatsu K, Sakakura K, Toyoda M et al (2012) Immunosuppressive activity of CD14(+) HLA-DR(−) cells in squamous cell carcinoma of the head and neck. Cancer Sci 103(6):976–983PubMedCrossRef

22.

Clayman GL, El-Naggar AK, Lippman SM et al (1998) Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16:2221–2232PubMed

23.

Clayton A, Al-Taei S, Webber J et al (2011) Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol 187:676–683PubMedCrossRef

24.

Cortesina G, De Stefani A, Galeazzi E et al (1994) Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. Br J Cancer 69:572–576PubMedCrossRef

25.

Couch ME, Ferris RL, Brennan JA et al (2007) Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer. Clin Cancer Res 13:7199–7206PubMedCrossRef

26.

Crombet T, Osorio M, Cruz T et al (2004) Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22:1646–1654PubMedCrossRef

27.

D’souza G, Dempsey A (2011) The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med 53(Suppl 1):5–11CrossRef

28.

De Stefani A, Forni G, Ragona R et al (2002) Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer 95:90–97CrossRef

29.

Dean NR, Knowles JA, Helman EE et al (2010) Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model. Anticancer Drugs 21:861–867PubMedCrossRef

30.

Deleo AB (1998) p53-based immunotherapy of cancer. Crit Rev Immunol 18:29–35PubMedCrossRef

31.

Dietz A, Wichmann G (2011) Translational research in head and neck cancer. Biological characteristics and general aspects. HNO 59:874–884PubMedCrossRef

32.

Figueiredo DL, Mamede RC, Spagnoli GC et al (2011) High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head Neck 33:702–707PubMedCrossRef

33.

Filho PA, Lopez-Albaitero A, Xi L et al (2009) Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer. Int J Cancer 125:1912–1920PubMedCrossRef

34.

Freeman SM, Franco JL, Kenady DE et al (2011) A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. Am J Clin Oncol 34:173–178PubMed

35.

Gastman BR, Johnson DE, Whiteside TL et al (2000) Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood 95:2015–2023PubMed

36.

Glazer CA, Smith IM, Bhan S et al (2011) The role of MAGEA2 in head and neck cancer. Arch Otolaryngol Head Neck Surg 137:286–293PubMedCrossRef

37.

Haddad R, Posner MR (2003) Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine. Clin Adv Hematol Oncol 1:226–228PubMed

38.

Hald J, Rasmussen N, Claesson MH (1995) Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol Immunother 41:243–250PubMedCrossRef

39.

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedCrossRef

40.

Heusinkveld M, Goedemans R, Briet RJ et al (2012) Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int J Cancer 131:E74–E85PubMedCrossRef

41.

Hoffmann T, Hafner D, Ballo H et al (1997) Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res 17:4419–4425PubMed

42.

Hoffmann TK, Donnenberg AD, Finkelstein SD et al (2002) Frequencies of tetramer + T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res 62:3521–3529PubMed

43.

Hoffmann TK, Dworacki G, Tsukihiro T et al (2002) Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8:2553–2562PubMed

44.

Hoffmann TK, Meidenbauer N, Dworacki G et al (2000) Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 60:3542–3549PubMed

45.

Hoffmann TK, Muller-Berghaus J, Ferris RL et al (2002) Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 8:1787–1793PubMed

46.

Hoffmann TK, Nakano K, Elder EM et al (2000) Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol 165:5938–5944PubMed

47.

Hoffmann TK, Trellakis S, Okulicz K et al (2011) Cyclin B1 expression and p53 status in squamous cell carcinomas of the head and neck. Anticancer Res 31:3151–3157PubMed

48.

Ikawa T, Eura M, Fukiage T et al (1989) Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer. Gan To Kagaku Ryoho 16:1438–1447PubMed

49.

Ikic D, Krusic J, Kirhmajer V et al (1981) Application of human leucocyte interferon in patients with carcinoma of the uterine cervix. Lancet 1:1027–1030PubMedCrossRef

50.

Ishikawa T, Ikawa T, Eura M et al (1989) Adoptive immunotherapy for head and neck cancer with killer cells induced by stimulation with autologous or allogeneic tumour cells and recombinant interleukin-2. Acta Otolaryngol 107:346–351PubMedCrossRef

51.

Junker N, Kvistborg P, Kollgaard T et al (2012) Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures. Cell Immunol 273:1–9PubMedCrossRef

52.

Kao H, Marto JA, Hoffmann TK et al (2001) Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 194:1313–1323PubMedCrossRef

53.

Karcher J, Dyckhoff G, Beckhove P et al (2004) Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res 64:8057–8061PubMedCrossRef

54.

Kass ES, Greiner JW, Kantor JA et al (2002) Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. Cancer Res 62:5049–5057PubMed

55.

Kienstra MA, Neel HB, Strome SE et al (2003) Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 25:457–463PubMedCrossRef

56.

Kies MS, Ghebremichael MS, Katz TL et al (2007) EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings. J Clin Oncol 25:6024

57.

Kim J, Modlin RL, Moy RL et al (1995) IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 155:2240–2247PubMed

58.

Kim JW, Wieckowski E, Taylor DD et al (2005) Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 11:1010–1020PubMed

59.

Kirby AM, A’hern RP, D’ambrosio C et al (2006) Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 94:631–636PubMed

60.

Kitahara S, Ikeda M, Inouye T et al (1996) Inhibition of head and neck metastatic and/or recurrent cancer by local administration of multi-cytokine inducer OK-432. J Laryngol Otol 110:449–453PubMedCrossRef

61.

Kurosaki M, Horiguchi S, Yamasaki K et al (2011) Migration and immunological reaction after the administration of alphaGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer. Cancer Immunol Immunother 60:207–215PubMedCrossRef

62.

Kuss I, Hathaway B, Ferris RL et al (2004) Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10:3755–3762PubMedCrossRef

63.

Lang S, Lauffer L, Clausen C et al (2003) Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor. FASEB J 17:286–288PubMed

64.

Lang S, Whiteside TL, Lebeau A et al (1999) Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. Arch Otolaryngol Head Neck Surg 125:82–88PubMedCrossRef

65.

Le Calvez F, Mukeria A, Hunt JD et al (2005) TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 65:5076–5083CrossRef

66.

Lee J, Moon C (2011) Current status of experimental therapeutics for head and neck cancer. Exp Biol Med (Maywood) 236:375–389

67.

Letessier EM, Sacchi M, Johnson JT et al (1990) The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer. Cell Immunol 130:446–458PubMedCrossRef

68.

Li JJ, Gu MF, Pan K et al (2012) Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother 35:189–195PubMedCrossRef

69.

Licitra L, Mesia R, Rivera F et al (2011) Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 22:1078–1087PubMedCrossRef

70.

Liu J, Lu G, Li Z et al (2010) Distinct compartmental distribution of mature and immature dendritic cells in esophageal squamous cell carcinoma. Pathol Res Pract 206:602–606PubMedCrossRef

71.

Lopez-Albaitero A, Nayak JV, Ogino T et al (2006) Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 176:3402–3409PubMed

72.

Machiels JP, Subramanian S, Ruzsa A et al (2011) Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 12:333–343PubMedCrossRef

73.

Mandruzzato S, Brasseur F, Andry G et al (1997) A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 186:785–793PubMedCrossRef

74.

Meissner M, Reichert TE, Kunkel M et al (2005) Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 11:2552–2560PubMedCrossRef

75.

Mellstedt H, Vansteenkiste J, Thatcher N (2011) Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 73:11–17PubMedCrossRef

76.

Meneses A, Verastegui E, Barrera JL et al (2003) Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2. Int Immunopharmacol 3:1083–1091PubMedCrossRef

77.

Mesia R, Rivera F, Kawecki A et al (2010) Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 21:1967–1973PubMedCrossRef

78.

Milenic DE, Brady ED, Brechbiel MW (2004) Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3:488–499PubMedCrossRef

79.

Mulligan JK, Day TA, Gillespie MB et al (2009) Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Hum Immunol 70:375–382PubMedCrossRef

80.

Okines AF, Ashley SE, Cunningham D et al (2010) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol 28:3945–3950PubMedCrossRef

81.

Postema EJ, Borjesson PK, Buijs WC et al (2003) Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer. J Nucl Med 44:1690–1699PubMed

82.

Rech AJ, Vonderheide RH (2009) Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 1174:99–106PubMedCrossRef

83.

Reichert TE, Strauss L, Wagner EM et al (2002) Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 8:3137–3145PubMed

84.

Rice SQ, Crane IJ, Scully C et al (1992) Production of a suppressor of lymphocyte proliferation by two human oral carcinoma cell lines. Scand J Immunol 36:443–452PubMedCrossRef

85.

Richtsmeier WJ, Koch WM, Mcguire WP et al (1990) Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma. Arch Otolaryngol Head Neck Surg 116:1271–1277PubMedCrossRef

86.

Riechelmann H, Sauter A, Golze W et al (2008) Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 44:823–829PubMedCrossRef

87.

Riechelmann H, Wiesneth M, Schauwecker P et al (2007) Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunol Immunother 56:1397–1406PubMedCrossRef

88.

Rosbe KW, Prazma J, Petrusz P et al (1995) Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 113:541–549PubMed

89.

Rubin Grandis J, Melhem MF, Gooding WE et al (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824–832CrossRef

90.

Saito T, Kuss I, Dworacki G et al (1999) Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 5:1263–1273PubMed

91.

Sauter A, Kloft C, Gronau S et al (2007) Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol 30:927–935PubMed

92.

Schilling B, Harasymczuk M, Schuler P et al (2012) IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model. J Mol Med (Berl) 90:139–147

93.

Schmitz S, Kaminsky-Forrett MC, Henry S et al (2012) Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol 23(8):2153–2161PubMedCrossRef

94.

Schmoll H, Höffken K, Possinger K (2006) Herkunft und Entstehung von Tumoren (Äthiologie), Kompendium Internistische Onkologie. Springer, S 235–278

95.

Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570PubMedCrossRef

96.

Schroeder P, Lindemann C, Dettmar K et al (2011) Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment. Clin Transl Oncol 13:889–898PubMedCrossRef

97.

Schuler PJ, Boeckers P, Engers R et al (2011) EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma. J Transl Med 9:168PubMedCrossRef

98.

Schuler PJ, Borger V, Bolke E et al (2011) Dendritic cell generation and CD4+ CD25high FOXP3+ regulatory t cells in human head and neck carcinoma during radio-chemotherapy. Eur J Med Res 16:57–62PubMedCrossRef

99.

Schuler PJ, Schilling B, Harasymczuk M et al (2012) Phenotypic and functional characteristics of ATP-hydrolysing CD4(+) CD39(+) FOXP3(+) and CD4(+) CD39(+) FOXP3(neg) T-cell subsets in patients with cancer. Eur J Immunol 42(7):1876–1885PubMedCrossRef

100.

Seixas-Silva JA Jr, Richards T, Khuri FR et al (2005) Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. Arch Otolaryngol Head Neck Surg 131:304–307PubMedCrossRef

101.

Sharkey RM, Hajjar G, Yeldell D et al (2005) A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 46:620–633PubMed

102.

Shibuya TY, Wei WZ, Zormeier M et al (1999) Anti-CD3/anti-CD28 monoclonal antibody-coated suture enhances the immune response of patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 125:1229–1234PubMedCrossRef

103.

Shichijo S, Nakao M, Imai Y et al (1998) A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 187:277–288PubMedCrossRef

104.

Shin DM, Khuri FR, Murphy B et al (2001) Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 19:3010–3017PubMed

105.

Shockley TR, Lin K, Nagy JA et al (1991) Penetration of tumor tissue by antibodies and other immunoproteins. Ann N Y Acad Sci 618:367–382PubMedCrossRef

106.

Siu LL, Soulieres D, Chen EX et al (2007) Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 25:2178–2183PubMedCrossRef

107.

Smith C, Tsang J, Beagley L et al (2012) Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 72(5):1116–1125PubMedCrossRef

108.

Snyderman CH, Klapan I, Milanovich M et al (1994) Comparison of in vivo and in vitro prostaglandin E2 production by squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 111:189–196PubMedCrossRef

109.

Soulieres D, Senzer NN, Vokes EE et al (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77–85PubMedCrossRef

110.

Squadrelli-Saraceno M, Rivoltini L, Cantu G et al (1990) Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2. Tumori 76:566–571PubMed

111.

Stewart JS, Cohen EE, Licitra L et al (2009) Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 27:1864–1871PubMedCrossRef

112.

Strauss L, Bergmann C, Gooding W et al (2007) The frequency and suppressor function of CD4+ CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13:6301–6311PubMedCrossRef

113.

Taylor SGT, Sisson GA, Bytell DE et al (1983) A randomized trial of adjuvant BCG immunotherapy in head and neck cancer. Arch Otolaryngol 109:544–549PubMedCrossRef

114.

Thiel A, Kesselring R, Pries R et al (2011) Plasmacytoid dendritic cell subpopulations in head and neck squamous cell carcinoma. Oncol Rep 26:615–620PubMed

115.

Tijink BM, Buter J, De Bree R et al (2006) A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 12:6064–6072PubMedCrossRef

116.

To WC, Wood BG, Krauss JC et al (2000) Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg 126:1225–1231PubMedCrossRef

117.

Uppaluri R, Dunn GP, Lewis JS Jr (2008) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun 8:16PubMed

118.

Urba SG, Forastiere AA, Wolf GT et al (1993) Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma. Cancer 71:2326–2331PubMedCrossRef

119.

Valone FH, Gandara DR, Deisseroth AB et al (1991) Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. J Immunother 10:207–213PubMedCrossRef

120.

Van Herpen CM, Van Der Voort R, Van Der Laak JA et al (2008) Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. Int J Cancer 123:2354–2361CrossRef

121.

Vermorken JB, Guigay J, Mesia R et al (2011) Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 104:1691–1696PubMedCrossRef

122.

Vermorken JB, Herbst RS, Leon X et al (2008) Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 112:2710–2719PubMedCrossRef

123.

Vermorken JB, Remenar E, Van Herpen C et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704PubMedCrossRef

124.

Victora GD, Socorro-Silva A, Volsi EC et al (2009) Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients. Cancer Gene Ther 16:598–608PubMedCrossRef

125.

Vlock DR, Andersen J, Kalish LA et al (1996) Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. J Immunother Emphasis Tumor Immunol 19:433–442PubMedCrossRef

126.

Vogl SE, Schoenfeld DA, Kaplan BH et al (1982) Methotrexate alone or with regional subcutaneous Corynebacterium parvum in the treatment of recurrent and metastatic squamous cancer of the head and neck. Cancer 50:2295–2300PubMedCrossRef

127.

Walz A, Andratschke M, Wollenberg B et al (2005) Prednisolone reduces TNF-alpha release by PBMCs activated with a trifunctional bispecific antibody but not their anti-tumor activity. Anticancer Res 25:4239–4243PubMed

128.

Wanebo HJ, Hilal EY, Strong EW et al (1978) Adjuvant trial of levamisole in patients with squamous cancer of the head and neck: a preliminary report. Recent Results Cancer Res 68:324–333PubMedCrossRef

129.

Wanebo HJ, Riley T, Katz D et al (1988) Indomethacin sensitive suppressor-cell activity in head and neck cancer patients. The role of the adherent mononuclear cell. Cancer 61:462–474PubMedCrossRef

130.

Wansom D, Light E, Worden F et al (2010) Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 136:1267–1273PubMedCrossRef

131.

Weber J (2007) Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12:864–872PubMedCrossRef

132.

Whiteside TL, Heo DS, Takagi S et al (1988) Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2. Cancer Immunol Immunother 26:1–10PubMedCrossRef

133.

Whiteside TL, Letessier E, Hirabayashi H et al (1993) Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res 53:5654–5662PubMed

134.

Whiteside TL, Mandapathil M, Szczepanski M et al (2011) Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. Bull Cancer 98:E25–E31PubMed

135.

Whiteside TL, Stanson J, Shurin MR et al (2004) Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol 173:1526–1534PubMed

136.

Wild CA, Brandau S, Lotfi R et al (2012) HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol 48(5):409–416PubMedCrossRef

137.

Wirth LJ, Allen AM, Posner MR et al (2010) Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 21:342–347PubMedCrossRef

138.

Wollenberg B, Zeidler R, Lebeau A et al (1998) Lack of B7.1 and B7.2 on head and neck cancer cells and possible significance for gene therapy. Int J Mol Med 2:167–171PubMed

139.

Yamasaki K, Horiguchi S, Kurosaki M et al (2011) Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 138:255–265PubMedCrossRef

140.

Zeidler R, Csanady M, Gires O et al (2000) Tumor cell-derived prostaglandin E2 inhibits monocyte function by interfering with CCR5 and Mac-1. FASEB J 14:661–668PubMed

141.

Zhang Y, Sturgis EM, Huang Z et al (2012) Genetic variants of the p53 and p73 genes jointly increase risk of second primary malignancies in patients after index squamous cell carcinoma of the head and neck. Cancer 118:485–492PubMedCrossRef

Titel: Immuntherapie von Kopf-Hals-Karzinomen
Aktuelle Entwicklungen
verfasst von: Dr. P.J. Schuler
T.K. Hoffmann
T.C. Gauler
C. Bergmann
S. Brandau
S. Lang
Publikationsdatum: 01.07.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: HNO / Ausgabe 7/2013
Print ISSN: 0017-6192
Elektronische ISSN: 1433-0458
DOI: https://doi.org/10.1007/s00106-012-2635-6

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Immuntherapie von Kopf-Hals-Karzinomen

Aktuelle Entwicklungen

Zusammenfassung

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2013

Behandlungskonzepte zur Rekonstruktion bei ausgedehnten Unterkieferdefekten

Primäres sinunasales Ameloblastom bei einer 49-jährigen Frau

Stellenwert der präoperativen Röntgendiagnostik der Nasennebenhöhlen vor Septumplastik

Behandlung chronischer Rhinosinusitis mit der Ballon-Sinuplastik

Evaluation des Freiburger Einsilbertests im Störschall

Mikrovaskulär anastomosierte Transplantate

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO